IRB #

STUDY00016702

Title

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors

Principal Investigator

Matthew Taylor

Study Purpose

This study is being done to test the good and bad effects of BMS-986158 as monotherapy and in combination with nivolumab in patients with select advance tumors.

Medical Condition(s)

Ovarian
Triple negative breast (TNBC)
Small cell lung cancer (SCLC)
Non small cell lung cancer (NSCLC)
Neuroendocrine prostate cancer
Renal Cell Carcinoma (RCC)
Uveal Melanoma
Uterine Carcinosarcoma
Etc.

Eligibility Criteria

1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 89

Healthy Volunteers Needed

No

Duration of Participation

You will receive the study drug as long as you and the investigator feel that you are tolerating the study drug and your disease is not getting worse. After you finish treatment, your doctor will continue to watch you for side effects and follow your condition every 3 months.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Bristol-Myers Squibb

Recruitment End

01/01/2020

Compensation Provided

No


Go Back